Actual Use Trial of Naproxen Sodium (Kiefer AUT)
An Actual Use Trial In A Simulated OTC Environment of an Extended-Release Over-the-Counter NSAID
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Hoover, Alabama, United States, 35226
-
McCalla, Alabama, United States, 35111-3406
-
Pinson, Alabama, United States, 35126
-
-
Arizona
-
Mesa, Arizona, United States, 85202
-
-
California
-
Anaheim, California, United States, 92801
-
Oceanside, California, United States, 92054
-
Yorba Linda, California, United States, 92886
-
-
Kansas
-
Overland Park, Kansas, United States, 66209
-
-
Maryland
-
Baltimore, Maryland, United States, 21228
-
-
Minnesota
-
Andover, Minnesota, United States, 55304
-
Elk River, Minnesota, United States, 55330
-
Fridley, Minnesota, United States, 55432
-
Northfield, Minnesota, United States, 55057-2434
-
Rosemount, Minnesota, United States, 55068
-
Roseville, Minnesota, United States, 55113
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
-
Savannah, Missouri, United States, 64485
-
St. Joseph, Missouri, United States, 64504
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87104
-
Albuquerque, New Mexico, United States, 87107
-
Taos, New Mexico, United States, 87571
-
-
Utah
-
Bountiful, Utah, United States, 84010
-
Hurricane, Utah, United States, 84737
-
Layton, Utah, United States, 84041
-
Ogden, Utah, United States, 84401
-
Salt Lake City, Utah, United States, 84121
-
Salt Lake City, Utah, United States, 84102
-
Syracuse, Utah, United States, 84075
-
West Jordan, Utah, United States, 84088
-
-
Virginia
-
Montpelier, Virginia, United States, 23192
-
Richmond, Virginia, United States, 23221
-
-
Washington
-
Bellevue, Washington, United States, 98007
-
Kenmore, Washington, United States, 98028
-
Snohomish, Washington, United States, 98290
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 12 years of age
- Report taking OTC analgesics for pain on at least 5 days in the last month
- Report having had pain at least once in the last 3 months lasting longer than 12 hours or that they believe would have lasted longer than 12 hours if they had not treated it
- Able to read and understand English
- Provide written informed consent (subjects 12-17 years of age provide written assent and/or parent or legal guardian provide written consent)
- Provide contact information
- Purchase the investigational product
Exclusion Criteria:
- Have participated in a trial involving OTC analgesics in the last 6 months
- They or someone else in the household work for a market research company, an advertising agency, a public relations firm, a pharmaceutical company, as a healthcare professional, or as part of a health care practice (eliminated for reasons of confidentiality or increased awareness of drugs and their labels)
- Have a history of known allergies to NSAIDs (i.e., naproxen, ibuprofen, aspirin, etc.)
- Have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days
- (Female subjects) are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
|
BAYH6689; oral tablet used as needed upon incidence of pain
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimated Percentage of Misuse for Non-Therapeutic Reasons
Time Frame: 28 days
|
The primary objective of this trial was to determine the percentage of non-therapeutic misuse.
Two aspects of consumer use of Aleve 24 Hour were examined: the frequency at which consumers exceeded the label-defined daily dose modified by those who did so for non-therapeutic reasons.
|
28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Non-therapeutic Reasons for Misuse
Time Frame: 28 days
|
Those subjects in the Reasons for Misuse Cohort who did not state misuse due to need for additional pain relief were categorized to Non-therapeutic misuse.
|
28 days
|
|
Estimated Percentage of Misuse for Non-Therapeutic Reasons Using the First 10-Day Treatment Course
Time Frame: 28 days
|
This endpoint was an assessment of whether the rate of non-therapeutic misuse exceeded the pre-defined acceptable threshold for non-therapeutic misuse.
The difference lay in the estimation of misuse in the Patterns of Use Cohort by using 10-day treatment courses rather than by "use day".
A treatment course for each subject began on the first day they recorded taking one or more tablets which was followed by nine consecutive "evaluable days."
|
28 days
|
|
Percentage of Participants Took >/= 2 Tablets/Use Day in Any 10 Use Days
Time Frame: 28 days
|
Percentage of participants took >/= 2 tablets/use day in any 10 use days thus exceeding the label directions during a treatment course.
|
28 days
|
|
Percentage of Participants Who Took Product With Mean Daily Use >/= 2 Tablets /Use Day
Time Frame: 28 days
|
Percentage of participants who took product with mean daily use >/= 2 tablets /use day thus exceeding the label directions on any use day.
|
28 days
|
|
Percentage of Participants With at Least One Dosing Occasion Where More Than One Tablet Was Taken
Time Frame: 28 days
|
Percentage of participants with at least one dosing occasion where more than one tablet was taken thus exceeding the label directions.
|
28 days
|
|
Percentage of Dosing Occasions Where More Than One Tablet Was Taken
Time Frame: 28 days
|
Percentage of dosing occasions where more than one tablet was taken thus exceeding the label directions.
|
28 days
|
|
Percentage of Participants Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose
Time Frame: 28 days
|
Percentage of participants where a dose was taken less than 22 hours after the most recent previous dose thus exceeding the label directions.
22 hrs was chosen to allow for some imprecision in subjects' recollection.
|
28 days
|
|
Percentage of Dosing Occasions Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose
Time Frame: 28 days
|
Percentage of dosing occasions where a dose was taken less than 22 hours after the most recent previous dose.
22 hrs was chosen to allow for some imprecision in subjects' recollection
|
28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gout Suppressants
- Naproxen
Other Study ID Numbers
Other Study ID Numbers
- 15647
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.